Neuroscience • 27 March 2017
London • United Kingdom

Agenda

27/03/2017

7:30 am - 8:30 am
The Francis Crick Institute
8:30 am - 8:50 am
The Francis Crick Institute
Welcome

Welcome messages.

  • Chief Academic Officer, Partners HealthCare
  • Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School
  • COO and Director of Scientific Translation, The Francis Crick Institute
8:50 am - 9:05 am
The Francis Crick Institute
Address from UK Dementia Envoy
  • UK Dementia Envoy; Chairman, Alzheimer's Research UK
9:05 am - 9:50 am
The Francis Crick Institute
Session 1 - Disease Modifying Therapies: Getting over the Technology Threshold

What are the investment priorities for new diagnostics and therapeutics? Are symptomatic therapies still viable?

  • Partner, Atlas Venture
  • Managing Partner, SVLS
  • SVP, Global Head of Neurosciences, GlaxoSmithKline
  • CEO, Roivant Sciences
  • EVP, Chief Medical Officer, Head, Development and Worldwide Medical, Biogen
  • Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital
  • Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School
9:50 am - 10:35 am
The Francis Crick Institute
Session 2 – Expanding the Diagnostic Spectrum: Tools, Technologies, and Tracers

The market for neurological diagnostics is growing rapidly and expected to reach $13.6 billion by 2019. Which technologies will drive this new system? When will they be deployed and what are key barriers? Will there be sufficient discrete financial incentives to achieve the necessary innovation?

  • Director, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
  • CSO, Imanova
  • Professor of Molecular Neuroimaging, Department of Medicine, Imperial College, London
  • Phyllis and Jerome Lyle Rappaport MGH Research Scholar, Director of Radiochemistry, Athinoula A. Martinos Center, Massachusetts General Hospital
  • Associate Professor in Radiology, Harvard Medical School
  • VP of MR Product Definition & Innovation, Siemens
  • CEO, Akili Interactive Labs
  • Professor of Neurochemistry, Head of Lab, UCL
  • Professor of Neurochemistry, Head of Department, University of Gothenburg
10:35 am - 10:55 am
The Francis Crick Institute
10:55 am - 11:20 am
The Francis Crick Institute
1:1 Fireside Chat with John Lechleiter, PhD
Moderator: Hilary Evans
  • CEO, Alzheimer’s Research UK
  • Chairman, Eli Lilly and Company
11:20 am - 11:45 am
The Francis Crick Institute
Patient Interview
  • Chair, Department of Neurology, Brigham and Women’s Hospital
  • Miriam Sydney Joseph Professor of Neurology, Harvard Medical School
  • Dementia Patient & Caregiver, Dementia Advocates and Volunteer Partners with ARUK (Alzheimer’s Research UK)
11:45 am - 12:30 pm
The Francis Crick Institute
Session 3 - Neurodegeneration and Neuroinflammation: A Grand Unifying Theory for Drug Development?

How will new immunity-focused insights and technologies drive neurodegeneration and neuroinflammatory diagnostics and therapies?

  • Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital
  • Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
  • Institute Head, German Center for Neurodegenerative Disease
  • President of Global R&D, CSO, Teva Pharmaceutical Industries
  • CSO, Neuroscience, Eli Lilly and Company
  • President, Neurimmune Holding AG
  • Professor of Experimental Neuropathology, University of Southampton
12:30 pm - 1:40 pm
Biogen Seminar Suite | The Francis Crick Institute
Lunch Breakout 1 - Women and Dementia

Women have unique brain health challenges as they are twice as likely as men to have dementia. Additionally, women often take on the responsibility of caring for a loved one with the disease. This breakout will explore the efforts in sex-based brain health research and current funding challenges.

Moderator: Phyllis Ferrell
  • VP, Global Alzheimer’s Disease Platform Team, Eli Lilly and Company
  • CEO, Alzheimer’s Research UK
  • President Women Against Alzheimer's
  • Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital
  • Professor of Neurology, Harvard Medical School
12:30 pm - 1:40 pm
Auditorium A | The Francis Crick Institute
Lunch Breakout 2 - Evolving Dementia Care: Government Policy in Action

How are the national dementia care strategies evolving? How does dementia care impact therapeutic innovation? Are we monitoring the impact of care beyond quality of life measures?

Moderator: Tim Ferris, MD
  • Senior Vice President of Population HealthCare Management, Partners HealthCare
  • Associate Professor of Medicine and Pediatrics, Harvard Medical School
  • Director of Health Social Care and Integration, Scottish Government
  • Executive Director, Alzheimer's Disease International
12:30 pm - 1:40 pm
Auditorium B | The Francis Crick Institute
Lunch Breakout 3 - Depression and Neuroinflammation

Depressed patients often have high levels of inflammatory biomarkers, supporting the idea that certain psychiatric disorders could be an inflammatory response. As over half of all people with depression do not respond to conventional therapies, this breakout will explore the emerging research in anti-inflammatory treatments for CNS.

  • VP Head of Circuits, Neuro-Opportunities & Screening, Technologies, Pfizer
  • VP, Neuroscience Lead, J&J London Innovation Centre, Johnson & Johnson
  • CSO, McLean Hospital
  • Professor in Psychiatry, Harvard Medical School
12:30 pm - 1:40 pm
The Francis Crick Institute
1:40 pm - 2:25 pm
The Francis Crick Institute
Session 4 - The Promise and Current Role of Gene and Cell Therapy as Treatments of Neurological Disease

Which diseases will be first? What are the barriers? When will there be clinical deployment?

  • Principal Investigator Harvard Stem Cell Institute, McLean Hospital
  • Professor of Neurology and Neuroscience, Harvard Medical School
  • Professor of Medicine Emeritus, Director of Research, Honorary Consultant Physician, University of Cambridge
  • Director, Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital
  • John B. Penney Professor of Neurology, Harvard Medical School
  • Deputy Chief Executive, National Institute for Health and Care Excellence
  • CEO, Voyager Therapeutics
2:25 pm - 3:10 pm
The Francis Crick Institute
Session 5 - Next-Generation Therapies and Diagnostics: Big Data and Digital Health

As new HIT-driven systems and products are identified, what will influence new therapies and diagnostics? Which technologies will scale the fastest? How large do cohorts have to be to provide meaningful insights? Are there examples of real world successes?

  • Corporate Director of Research Information Systems and Computing, Partners HealthCare
  • Associate Professor of Neurology, Harvard Medical School
  • CSO, Cambridge Cognition
  • Director, MRC Dementias Platform UK
  • Global Therapeutic Area Head, Neuroscience, Janssen R&D
  • VP Development Sciences, Biogen
  • Director, Multiple Sclerosis Program, Brigham and Women's Hospital
  • Robert L. Kroc Professor of Neurology, Harvard Medical School
3:10 pm - 3:35 pm
The Francis Crick Institute
3:35 pm - 3:55 pm
The Francis Crick Institute
3:55 pm - 4:40 pm
The Francis Crick Institute
Session 6 - Implementing Novel Models in Alzheimer’s Trials: How Can We Transform the Cost-Benefit Equation for Trials?

With an expanding Alzheimer’s pipeline, design challenges continue to limit the flexibility of trial execution. Which emerging solutions (e.g. digital technologies, data sharing, patient recruitment, alternative endpoints) will transform cost, duration, or value generated from future Alzheimer’s trials?

  • Director, Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital
  • Professor of Neurology, Harvard Medical School
  • VP Neuroscience IMED MedImmune, AstraZeneca
  • Global Head of Quantitative Sciences, Janssen Pharmaceuticals
  • Professor of Psychiatry of Ageing University of Edinburgh
  • President, AiM Institute, Eisai
4:40 pm - 5:25 pm
The Francis Crick Institute
Session 7 – The Crisis We Want: Are Healthcare Systems Prepared for a Disease-Modifying Drug?

There are currently 17 Alzheimer’s drugs entering Phase III over the next five years. What will be the response from payors, clinicians, and patient groups when those drugs finally reach patients? How can we find, treat, and provide drug access to all the right patients?

  • Chair, Department of Neurology, Massachusetts General Hospital
  • Julieanne Dorn Professor of Neurology, Harvard Medical School
  • VP, Global Alzheimer’s Disease Platform Team, Eli Lilly and Company
  • Senior Vice President of Population HealthCare Management, Partners HealthCare
  • Associate Professor of Medicine and Pediatrics, Harvard Medical School
  • Director of Health Social Care and Integration, Scottish Government
  • CEO, Otsuka America Pharmaceutical
5:25 pm - 6:00 pm
The Francis Crick Institute
Announcement and Discussion of the Springboard Challenge
  • Chief Innovation Officer, Partners HealthCare
  • SVP, R&D Pipeline GlaxoSmithKline
6:00 pm - 6:15 pm
The Francis Crick Institute
Forum Close
  • Chief Academic Officer and SVP of Research, Brigham and Women’s Hospital
  • K. Frank Austen Professor of Medicine, Harvard Medical School
  • SVP for Research, MassGeneral Research Institute, Massachusetts General Hospital
6:15 pm - 8:00 pm
The Francis Crick Institute

*Panels and speakers are subject to change.